Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells

Journal of Virology

Volumn 80, Issue 1, 2006, Pages 383-394

  Efferson, Clay L ^a   Tsuda, Naotake ^a   Kawano, Kouichiro ^a   Nistal Villán, Estanislao ^b   Sellappan, Shankhar ^a   Yu, Dihua ^a   Murray, James L ^a   Garcia Sastre, Adolfo ^b   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINO ACID; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN NS1; RAS PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INFLUENZA VIRUS; INFLUENZA VIRUS A; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; HUMANS; INFLUENZA A VIRUS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRAL NONSTRUCTURAL PROTEINS;

ANIMALIA; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZAVIRUS A; ORTHOMYXOVIRIDAE;

EID: 33645984243     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.1.383-394.2006     Document Type: Article

References (50)

1. Ahmed, A., J. Thompson, L. Emiliusen, S. Murphy, R. D. Beauchamp, K. Suzuki, R. Alemany, K. Harrington, and R. G. Vile. 2003. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol. 21:771-777.
2. Anderson, B. W., G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides. 2000. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin. Cancer Res. 6:4192-4200.
3. Arlen, P. M., J. L. Gulley, K. Y. Tsang, and J. Schlom. 2003. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert Rev. Vaccines 2:483-493.
4. Babcock, B., B. W. Anderson, I. Papayannopoulos, A. Castilleja, J. L. Murray, S. Stifani, A. P. Kudelka, J. T. Wharton, and C. G. Ioannides. 1998. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol. Immunol. 35:1121-1133.
5. Balachandran, S., and G. N. Barber. 2004. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65.
6. Bateman, A. R., K. J. Harrington, T. Kottke, A. Ahmed, A. A. Melcher, M. J. Gough, E. Linardakis, D. Riddle, A. Dietz, C. M. Lohse, S. Strome, T. Peterson, R. Simari, and R. G. Vile. 2002. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res. 62:6566-6578.
7. Bell, W. C., R. B. Myers, T. O. Hosein, D. K. Oelschlager, and W. E. Grizzle. 2003. The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech. Histochem. 78:11-16.
8. Bergmann, M., I. Romirer, M. Sachet, R. Fleischhacker, A. García-Sastre, P. Palese, K. Wolff, H. Pehamberger, R. Jakesz, and T. Muster. 2001. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 61:8188-8193.
9. Castilleja, A., D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, and C. G. Ioannides. 2002. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J. Immunol. 169:3545-3554.
10. Castilleja, A., N. E. Ward, R. B. Epstein, A. P. Kudelka, D. M. Gershenson, C. L. Efferson, C. A. O'Brian, and C. G. Ioannides. 2002. Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro. Oncol. Rep. 9:929-935.
11. Clark, J. A., A. R. Black, O. V. Leontieva, M. R. Frey, M. A. Pysz, L. Kunneva, A. Woloszynska-Read, D. Roy, and J. D. Black. 2004. Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J. Biol. Chem. 279:9233-9247.
12. Correale, P., K. Walmsley, C. Nieroda, S. Zaremba, M. Zhu, J. Schlom, and K. Y. Tsang. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293-300.
13. de la Luna, S., P. Fortes, A. Beloso, and J. Ortin. 1995. Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs. J. Virol. 69:2427-2433.
14. Efferson, C. L., J. Schickli, B. K. Ko, K. Kawano, S. Mouzi, P. Palese, A. García-Sastre, and C. G. Ioannides. 2003. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTL) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. J. Virol. 77:7411-7424.
15. Enami, K., T. A. Sato, S. Nakada, and M. Enami. 1994. Influenza virus NS1 protein stimulates translation of the M1 protein. J. Virol. 68:1432-1437.
16. Farassati, F., A. D. Yang, and P. W. Lee. 2001. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3:745-750.
17. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
18. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:2109-2117.
19. Fisk, B., and C. G. Ioannides. 1998. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. Cancer Res. 58:4790-4793.
20. García-Sastre, A., A. Egorov, D. Matassov, S. Brandt, D. E. Levy, J. E. Durbin, P. Palese, and T. Muster. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330.
21. Giedlin, M. A., D. N. Cook, and T. W. Dubensky, Jr. 2003. Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? Cancer Cell 4:241-243.
22. Guo, C., L. M. Luttrell, and D. T. Price. 2000. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines, J. Urol. 163:1027-1032.
23. Hinshaw, V. S., C. W. Olsen, N. Dybdahl-Sissoko, and D. Evans. 1994. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J. Virol. 68:3667-3673.
24. Huang, T. G., O. Ebert, K. Shinozaki, A. García-Sastre, and S. L. Woo. 2003. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol. Ther. 8:434-440.
25. Konishi, N., Y. Hiasa, T. Tsuzuki, M. Tao, T. Enomoto, and G. J. Miller. 1997. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 30:53-57.
26. + cells in healthy individuals. Oncol. Rep. 7:455-466.
27. Lopez, C. B., A. Garcia-Sastre, B. R. G. Williams, and T. M. Moran. 2003. Type I Interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J. Infect. Dis. 187:1126-1136.
28. Ludwig, S., O. Planz, S. Pleschka, and T. Wolff. 2003. Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol. Med. 9:46-52.
29. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. Bushkin, D. M. Davis, J. L. Strominger, J. W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055-1060.
30. Mundschau, L. J., and D. V. Faller. 1992. Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J. Biol. Chem. 267:23092-23098.
31. Murray, J. L., M. E. Gillogly, D. Przepiorka, H. Brewer, N. K. Ibrahim, D. J. Booser, G. N. Hortobagyi, A. P. Kudelka, K. H. Grabstein, M. A. Cheever, and C. G. Ioannides. 2002. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8:3407-3418.
32. Muster, T., J. Rajtarova, M. Sachet, H. Unger, R. Fleischhacker, I. Romirer, A. Grassauer, A. Url, A. Garcia-Sastre, K. Wolff, H. Pehamberger, and M. Bergmann. 2004. Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int. J. Cancer 110:15-21.
33. Norman, K. L., K. Hirasawa, A. D. Yang, M. A. Shields, and P. W. Lee. 2004. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. USA 101:11099-11104.
34. Olschlager, V., S. Pleschka, T. Fischer, H. J. Rziha, W. Wurzer, L. Stitz, U. R. Rapp, S. Ludwig, and O. Planz. 2004. Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice. Oncogene 23:6639-6646.
35. Pleschka, S., T. Wolff, C. Ehrhardt, G. Hobom, O. Planz, U. R. Rapp, and S. Ludwig. 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3:301-305.
36. Quinlivan, M., D. Zamarin, A. García-Sastre, A. Cullinane, T. Chambers, and P. Palese. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79:8431-8439.
37. Ren, H., T. Boulikas, K. Lundstrom, A. Soling, P. C. Warnke, and N. G. Rainov. 2003. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J. Neurooncol. 64:147-154.
38. Salvatore, M., C. F. Basler, J.-P. Parisien, C. M. Horvath, S. Bourmakina, H. Zheng, T. Muster, P. Palese, and A. García-Sastre. 2002. Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J. Virol. 76:1206-1212.
39. Sellappan, S., R. Grijalva, X. Zhou, W. Yang, M. B. Eli, G. B. Mills, and D. Yu. 2004. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 64:3479-3485.
40. Shah, A. C., D. Benos, G. Y. Gillespie, and J. M. Markert. 2003. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65:203-226.
41. Sieczkarski, S. B., H. A. Brown, and G. R. Whittaker. 2003. Role of protein kinase C βII in influenza virus entry via late endosomes. J. Virol. 77:460-469.
42. Sinkovics, J. G., and J. C. Horvath. 2000. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 16:1-15.
43. Solórzano, A., R. J. Webby, K. M. Lager, B. H. Janke, A. García-Sastre, and J. A. Richt. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 79:7535-7543.
44. Stewart, J. R., and C. A. O'Brian. 2004. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Investig. New Drugs 22:107-117.
45. Stojdl, D. F., B. D. Lichty, B. R. tenOever, J. M. Paterson, A. T. Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, H. Atkins, E. G. Brown, R. K. Durbin, J. E. Durbin, J. Hiscott, and J. C. Bell. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
46. Talon, J., M. Salvatore, R. E. O'Neill, Y. Nakaya, H. Zheng, T. Muster, A. Garcia-Sastre, and P. Palese. 2000. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl. Acad. Sci. USA 97: 4309-4314.
47. Valenzuela, J., C. Schmidt, and M. Mescher. 2002. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J. Immunol. 169:6842-6849.
48. Wurzer, W. J., O. Planz, C. Ehrhardt, M. Giner, T. Silberzahn, S. Pleschka, and S. Ludwig. 2003. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J. 22:2717-2728.
49. Yeh, S., H. K. Lin, H. Y. Kang, T. H. Thin, M. F. Lin, and C. Chang. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA. 96:5458-5463.
50. Zhirnov, O. P., T. E. Konakova, T. Wolff, and H. D. Klenk. 2002. NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 76:1617-1625.